Mei-Ching Liu M.D.

Hematology and Medical Oncology
Medical Team: Breast Cancer, Colo-Rectal Cancer

Current Title

  • Senior Member, Division of Hematology and Medical Oncology, 1991-present

Clinical Interests

  • Clinical trials
  • Breast cancer
  • Colorectal cancer

Languages Spoken

  • English
  • Mandarin Chinese
  • Taiwanese

Education and Training

1978 National Taiwan University Medical College, Taiwan, MD, Medicine
1978-1981 Residency, National Taiwan University Hospital, Taiwan 
1981-1982 Fellowship, National Taiwan University Hospital, Taiwan
1986-1987 Clinical Fellowship, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Professional Experience

1982-2004 Attending Physician (Part-Time), National Taiwan University Hospital, Taiwan
1982-1991 Attending Physician, Taipei Medical College Hospital, Taiwan
1988-present Associate Professor, Internal Medicine, Taipei Medical College Hospital, Taiwan
1988-1991 Chief, Laboratory Medicine, Taipei Medical College Hospital, Taiwan
1991-2006 Chief, Hemato-oncology, Koo Foundation Sun Yat-Sen Cancer Center, Taiwan
1999-2009 Director, Breast Functional Group, Koo Foundation Sun Yat-Sen Cancer Center, Taiwan
2006-2008 Chief, Medicine, Koo Foundation Sun Yat-Sen Cancer Center, Taiwan
2008-present Senior Member, Hemato-oncology, Koo Foundation Sun Yat-Sen Cancer Center, Taiwan

Professional Memberships

  • Member, Taiwan Society of Hematology
  • Member, Taiwan Society of Internal Medicine
  • Member, Taiwan Academy of Hospice Palliative Medicine
  • Member, Taiwan Society of Breast Cancer
  • Member, The Chinese Oncology Society 

Selected Publications, 52 total

Listed publications from 1990-present

  1. Heather-Jane Au, Valerie Bee, Arlene Chan, Wolfgang Eiermann, Jean-Marc Ferrero,Tommy Fornander,John Glaspy,Deepa Lalla, Mei-Ching Liu,John Mackey, Miguel Martin, Dave P. Miller, Marek Pawlicki, Tadeusz Pienkowski, Tamas Pinter,Nicholas J. Robert, Maria Santana,Sandeep Sehdev,Dennis J. Slamon, Health-Related Quality of Life with Adjuvant Docetaxel and Trastuzumab-Based Regimens in Patients with Node-Positive, and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG-006 Study. Oncologist 2013 (to be edited)
  2. Gianni L,1 Pienkowski T,2 Im Y-H,3 Roman L,4 Tseng L-M,5 Liu M-C,6 Lluch A,7 Staroslawska E,8 de la Haba-Rodriguez J,9 Im S-A,10 Pedrini JL,11 Poirier B,12 Morandi P,13 Semiglazov V,14 Srimuninnimit V,15 Bianchi G,16 Szado T,17 Ratnayake J,18 Ross G,18 Valagussa P19 . Efficacy and safety analysis of a neoadjuvant randomized Phase II study of pertuzumab and trastuzumab (‘NeoSphere’) in women with locally advanced, inflammatory or early HER2-positive breast cancer.Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.
  3. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83.
  4. Yu-Yi Huang, MD, Dong-Ling You, MD, Mei-Ching Liu, MD, Tran-Der Tan, MD, Pei-Ing Lee, MD, Ming-Yuan Lee,MD. Underperformance of Gallium-67 Scan is Greater in Relapse Than in Initial Staging, Compared With FDG PET. Clinical Nuclear Medicine Volume 36, Number 10, October 2011.
  5. Yang PS. Chen CM. Liu MC. Jian JM. Horng CF. Liu MJ. Yu BL. Lee MY. Chi CW. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status. International Journal of Radiation Oncology, Biology, Physics. 77(2):516-22, 2010 Jun. [Journal Article]
  6. Shin-Cheh Chen, MD; Chao-Jung Tsao, MD; Mei-Ching Liu, MD; Dah-Cherng Yeh,MD; Ming-Feng Hou, MD; Tsai-Wang Chang, MD; Ruey-Kuen Hsieh, MD; Tsui-Yi Chao, MD; Cheng-Jeng Tai,MD; Nai-Shun Yao, MD; Hui-Ling Wu, MD; Chiun-Sheng Huang, MD, PhD, MPH.Treatment of ErbB2(HER2)-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access program - the Taiwan experience. Breast Cancer Research And Treatment (submitted).
  7. Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA,Martin M.Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negativeadvanced breast cancer. Breast Cancer Res Treat. 2010 May;121(1):121-31. Epub 2010 Mar 26.
  8. Tony MOK, Tsai-Shen YANG, Yee CHAO, Cheng-Hsu WANG, Mei-Ching Lin, Yoon Koo KANG, Won Ki KANG, Jun Suk KIM, Yajie WANG and Thomas LEUNG. Phase II study of irinotecan in combination with capecitabine as a first-line chemotherapy in Asian patients with inoperable hepatocellular carcinoma. Asian-pacific journal of clinical oncology 2009; 5: 95-100.
  9. Li-Jen Kuo, Mei-Ching Liu, James Jer-Min Jian, Cheng-Fang Horng, Tsun-I Cheng, Chung-Ming Chen, Wei-Tse Fang, and Yih-Lin Chung. Is Final TNM Staging A Predictor for Survival in Locally Advanced Rectal Cancer after Preoperative Chemoradiation Therapy? Annals of surgical oncology 2007 DOI: 10.1245/s10434-007-9471-z
  10. Li-Han Hsu, Thomas C. Soong, An-Chen Feng, MPH, Mei-Ching Liu, Intrapleural Urokinase for the Treatment of Loculated Malignant Pleural Effusions and Trapped Lungs in Medically Inoperable Cancer Patients. Journal of Thoracic Oncology Volume 1, Number 5, June 2006.
  11. Ming-Yuan Lee, Tran-Der Tan, An-Chen Feng, Mei-Ching Liu, Clinicopathological Analysis of malignant Lymphoma in Taiwan, Defined According to the World Health Organization Classification. Haematologica/The Hematology Journal, 2005; 90(12) P.1703-1705.
  12. Jason Chia-Hsien Cheng, Mei-Ching Liu, Stella Y. Tsai et al., Unexpectedly Frequent Hepatitis B Reactivation by Chemoradiation in Postgastrectomy Patients. CANCER November 1, 2004/volume101/Number 9 P.2126-2132.
  13. Li-Jen Kuo, Mig-Chih Chern, Mei-Hua Tsou, Mei-Ching Liu, James Jer-Min Jian, Chung-Ming Chen, Yih-Lin Chung, Wei-Tse Fang. Interpretation of Magnetic Resonance Imaging for Locally Advanced Rectal Carcinoma After Preoperative Chemoradiation Therapy. Dis Colon Rectum, January 2005 Vol. 48, No.1 pp23-28
  14. Li-Jen Kuo, Shuh-Yan Leu, Mei-Ching Liu, Chung-Ming Chen. Disseminated Intravascular Coagulation in AStagy IV Colon Patient:Report of A Case and Review of the Literature. Formos JSurg 2003; 36:188-192
  15. Li-Jen Kuo, M.D., Shuh-Yan Leu, M.D., Mei-Ching Lin, M.D., James Jer-Min Jian, M.D., Skye Hongiun Cheng, M.D., Chung-Ming Chen, M.D. How Aggressive Should We Be in Patients With Stage IV Colorectal Cancer? Dis Colon Rectum, December 2003 Vol.46, No. 12 p1646-1652.
  16. Jason Chia-Hsien Cheng, Chii-Ming Chen, Mei-Ching Liu, Mei-Hua Tsou, Po-Sheng Yang. Locoregional Failure of Postmastectomy Patients with 1-3 Positive Axillary Lymph Nodes Without Adjuvant Radiotherapy. Int. J. Radiation Oncology Biol. Phys., vol. 52, No. 4, pp. 980-988, 2002.
  17. Cheng-I Hsieh, Mei-Chin Liu, Skye H, Cheng, Tsang-Wu Liu, Chii-Ming Chen, Chris M.C.Chen, Mei-Hua Tsou, and Andrew T. Huang, M.D.: Adjuvant Sequential Chemotherapy With Doxorubicin Plus Cyclophosphamide, Methotrexate, and Fluorouracil (ACMF) With Concurrent Radiotherapy in ResectableAdvanced Breast Cancer. Am J. Clin Oncol(CCT)23(2): 122-127, 2000.(SCI)
  18. You DL, Liu MC, Tai YC, Tsou, MH : Gallium 67 scan in granulocytic sarcoma Ann. Nu Med Sci,. 14:125~128, 2001.
  19. S.K. Cheng, M.H. Tsou.M.C. Liu et. al.: Clnique Features of Breast Cancer in Taiwan Breast Cancer Research and Treatment J. Cancer and Treatment 63:213-223 2000.
  20. Jason Chia-H Sien Cheng, Chii Ming Chen, Mei-Ching Liu Locoregional Recurrence in Patients with One to Three Positive Axillary Nodes after Mastectomy Without Adjuvant Radiotherapy J. Formosa Med Assoc, 2000 Vol 99 No 10. (SCI)
  21. Cheng SH, Chen CM, Liu MC, Huang AT. Clinical Practice Guidelines for Breast Cancer. J. Chinese Oncol. Soc 1999; 15:12~28.
  22. SH Cheng, Jian JM, Chen KY, YU Tsaiyc, Liu MC, Chen CM: The Benefit and risk of postmastertomy radiation therapy in high risk breast cancer. Am J. clin oncol 21(1):12-17, 1998(SCI).
  23. Ch'ang HJ, Jian JM, Cheng SH,Liu MC, Leu SY, Wang KY, Tsai SYC, Tsao MH,   Lin HH, Huang AT. Sung JL.  Preoperative Concurrent Chemotherapy and Radiotherapy in Rectal Cancer Patients.  J. Formos Med Assoc. 97(1): 32-37, 1998.
  24. Cheng SH, Liu TW, Jian JM, Tsai SYC, Hao SP, Huang CH,Liu MC, Ben Yu, Huang AT. Concomitant Chemotherapy and Radiotherapy for Locally Advanced Nasopharyngeal Carcinoma.  Cancer J Sci Am 3(2): 100-106, 1997.
  25. Ch'ang' HJ, Cheng SH, Liu MC, Jian JM, Chen CM.  Postoperative Concurrent Chemotherapy and Radiotherapy for Resectable Locally Advanced Gastric Cancer Patients. A Preliminary Report.  Therapeut Radiol Oncol 4: 195-201, 1997.
  26. 陳榮邦, 鄭鴻鈞, 詹光裕, 劉美瑾: 磁振造影對評估食道癌腫瘤範圍的前瞻性研究。台灣醫界40卷第2期10-12頁, 1997年。
  27. Cheng SH, Chen CM, Jian JM, Tsai SYC, Liu TW,Liu MC, Chen MC, Lin HH.  Breast-Conserving Surgery and Radiotherapy for Early Breast Cancer.  J Formosa Med Assoc 95:372-7, 1996.
  28. Cheng SH, Chan WP, Lin YM, Liu MC, Chan KY, Jian JM. Magnetic Resonance Imaging in the Determination of Radiation Treatment Volume in Esophageal Carcinoma. J. Chinese Oncol. Soc. 11: 25-32, 1995.
  29. Liu MC, Hai A, Huang AT. Cancer and Epidemiology in the Far East: Contrast with the United States. Oncology Vol 7, No. 6, June 1993: 99-110.
  30. Yen ML, Chen YC, Lin MT, Liu MC, Tang JL, Wang CH, Hsieh CY : High dose chemotherapy with support by autologous bone marrow and GM/CSF in the treatment of advanced ovarian cancer: preliminary report of a new strategy. Transplantation Proceedings, 1992;24:1533-5.
  31. Tang JL, Lin MT, Liu MC, Wang CH, Lui LT, Chen YC. Successful reinduction of remission with low-dose ARA-C in a patient with myelodysplastic syndrome relapsed after allogeneic bone marrow transplantation: restoration of donor hematopoiesis detectd by amplification of minisatellite genes.  Transplantation Proceedings, Vol 24, No 4 (August),1992 : pp 1522-1523.

Principal Investigator of International Clinical Trials, 24 total

TOP
Copyright © Koo Foundation Sun Yat-Sen Cancer Center 125 Lih-Der Road, Pei-Tou District, Taipei, Taiwan. Tel:+886 2 2897-0011